Search

Your search keyword '"Schulte, Peter"' showing total 551 results
Start Over Author "Schulte, Peter"

Refine your results

more »

more »

more »

more »

more »
551 results on '"Schulte, Peter"'

4. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies

Author

Ruan, Can-Jun, Olmos, Ismael, Ricciardi, Carina, Schoretsanitis, Georgios, Vincent, Philippe D., Anıl Yağcıoğlu, A. Elif, Eap, Chin B., Baptista, Trino, Clark, Scott R., Fernandez-Egea, Emilio, Kim, Se Hyun, Lane, Hsien-Yuan, Leung, Jonathan, Maroñas Amigo, Olalla, Motuca, Mariano, Every-Palmer, Susanna, Procyshyn, Ric M., Rohde, Christopher, Suhas, Satish, Schulte, Peter F.J., Spina, Edoardo, Takeuchi, Hiroyoshi, Verdoux, Hélène, Correll, Christoph U., Molden, Espen, De Las Cuevas, Carlos, and de Leon, Jose

Published
2024
Full Text
View/download PDF

7. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition

Author

Schoretsanitis, Georgios, Anıl Yağcıoğlu, A. Elif, Ruan, Can-Jun, Eap, Chin B., Molden, Espen, Baptista, Trino, Clark, Scott R., Fernandez-Egea, Emilio, Kim, Se Hyun, Lane, Hsien-Yuan, Leung, Jonathan, Maroñas Amigo, Olalla, Motuca, Mariano, Olmos, Ismael, Every-Palmer, Susanna, Procyshyn, Ric M., Rohde, Christopher, Satish, Suhas, Schulte, Peter F.J., Spina, Edoardo, Takeuchi, Hiroyoshi, Verdoux, Hélène, Correll, Christoph U., and de Leon, Jose

Published
2024
Full Text
View/download PDF

9. Guía internacional para una dosificación más segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la proteína C reactiva y los niveles de clozapina

Author

de Leon, Jose, Schoretsanitis, Georgios, Smith, Robert L., Molden, Espen, Solismaa, Anssi, Seppälä, Niko, Kopeček, Miloslav, Švancer, Patrik, Olmos, Ismael, Ricciardi, Carina, Iglesias-Garcia, Celso, Iglesias-Alonso, Ana, Spina, Edoardo, Ruan, Can-Jun, Wang, Chuan-Yue, Wang, Gang, Tang, Yi-Lang, Lin, Shih-Ku, Lane, Hsien-Yuan, Kim, Yong Sik, Kim, Se Hyun, Rajkumar, Anto P., González-Esquivel, Dinora F., Jung-Cook, Helgi, Baptista, Trino, Rohde, Christopher, Nielsen, Jimmi, Verdoux, Hélène, Quiles, Clelia, Sanz, Emilio J., De las Cuevas, Carlos, Cohen, Dan, Schulte, Peter F.J., Ertuğrul, Aygün, Anıl Yağcıoğlu, A. Elif, Chopra, Nitin, McCollum, Betsy, Shelton, Charles, Cotes, Robert O., Kaithi, Arun R., Kane, John M., Farooq, Saeed, Ng, Chee H., Bilbily, John, Hiemke, Christoph, López-Jaramillo, Carlos, McGrane, Ian, Lana, Fernando, Eap, Chin B., Arrojo-Romero, Manuel, Rădulescu, Flavian Ştefan, Seifritz, Erich, Every-Palmer, Susanna, Bousman, Chad A., Bebawi, Emmanuel, Bhattacharya, Rahul, Kelly, Deanna L., Otsuka, Yuji, Lazary, Judit, Torres, Rafael, Yecora, Agustin, Motuca, Mariano, Chan, Sherry Kit Wa, Zolezzi, Monica, Ouanes, Sami, De Berardis, Domenico, Grover, Sandeep, Procyshyn, Ric M., Adebayo, Richard A., Kirilochev, Oleg O., Soloviev, Andrey, Fountoulakis, Konstantinos N., Wilkowska, Alina, Cubała, Wiesław Jerzy, Ayub, Muhammad, Silva, Alzira, Bonelli, Raphael M., Villagrán-Moreno, José María, Crespo-Facorro, Benedicto, Temmingh, Henk, Decloedt, Eric, Pedro, Maria Rosel, Takeuchi, Hiroyoshi, Tsukahara, Masaru, Gründer, Gerhard, Sagud, Marina, Celofiga, Andreja, Ignjatovic Ristic, Dragana, Ortiz, Bruno Bertolucci, Elkis, Helio, Pacheco Palha, António José, Llerena, Adrián, Fernandez-Egea, Emilio, Siskind, Dan, Weizman, Abraham, Masmoudi, Rim, Mohd Saffian, Shamin, Leung, Jonathan G., Buckley, Peter F., Marder, Stephen R., Citrome, Leslie, Freudenreich, Oliver, Correll, Christoph U., and Müller, Daniel J.

Published
2023
Full Text
View/download PDF

12. Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial.

Author

den Toom, Manouk, Blanken, Laura, Horn, Inge, Veerman, Selene, van der Vlugt-Molenaar, Joris J. B., de Koning, Mariken B., Bogers, Jan, Enterman, John, de Jonge, Martin, Cianci, Daniela, Frederix, Gerardus W. J., de Haas, Hans J., Storosum, Bram W., Veereschild, Mike, Javadzadeh, Martin, Schulte, Peter F. J., Cohen, Dan, van Os, Jim, Cahn, Wiepke, and de Haan, Lieuwe

Subjects
MEDICAL research ethics, ELECTROCONVULSIVE therapy, SCHIZOPHRENIA, MEDICAL ethics committees, ACADEMIC medical centers
Abstract

Background Currently, guidance on the most effective treatment for patients with clozapine-resistant schizophrenia-spectrum disorders (SSD) is lacking. While augmentation strategies to clozapine with aripiprazole and electroconvulsive therapy (ECT) have been demonstrated to be effective in patients with clozapine-resistant schizophrenia spectrum disorders (CRS), head-to-head comparisons between these addition strategies are unavailable. We therefore aim to examine the feasibility of a larger randomized, single-blind trial comparing the effectiveness, cost-effectiveness, and safety of aripiprazole addition vs. ECT addition in CRS. Methods In this multi-center, randomized, single-blind feasibility study, the feasibility of recruiting 20 participants with CRS who will be randomized to either aripiprazole or bilateral ECT addition will be assessed. The main endpoint is the number of patients willing to be randomized. The number of screened individuals and reasons to decline participation will be recorded. Effects will be estimated for the benefit of the foreseen larger trial. To that end, differences between both arms in symptom severity will be assessed using blinded video assessments. In addition, tolerability (e. g., cognitive functioning), safety, quality of life, recovery, and all-cause discontinuation will be compared. The follow-up period is 16 weeks, after which non-responders will be given the option to switch to the other treatment. Discussion Strengths of this feasibility trial include maintaining blinding with video assessment, a possibility to switch groups in case of non-response, and a broad set of outcome measures. Identification of factors contributing to non-participation and drop-out will generate valuable information on trial feasibility and may enhance recruitment strategies in a follow-up RCT. Trial registration The study has been approved by the Medical Research Ethics Committee of the Amsterdam University Medical Center, location AMC, and was registered on 1 May 2022 in the EU Clinical Trials Register (EudraCT) under the trial name 'EMECLO' (2021–006333–19). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

Author

De las Cuevas, Carlos; https://orcid.org/0000-0001-5742-905X, Sanz, Emilio J; https://orcid.org/0000-0001-6788-4435, Gross, Jason A; https://orcid.org/0009-0000-9696-8267, Correll, Christoph U; https://orcid.org/0000-0002-7254-5646, Verdoux, Hélène; https://orcid.org/0000-0003-2948-3782, Lally, John; https://orcid.org/0000-0003-3038-0625, de Filippis, Renato; https://orcid.org/0000-0001-6928-1224, Schulte, Peter F J; https://orcid.org/0000-0003-4931-3393, Molden, Espen; https://orcid.org/0000-0001-6190-2751, Arrojo-Romero, Manuel; https://orcid.org/0000-0002-5609-7134, Bostrom, Adrian D; https://orcid.org/0000-0001-8604-9638, Schoretsanitis, Georgios; https://orcid.org/0000-0002-3851-4117, Fernandez-Egea, Emilio; https://orcid.org/0000-0003-4128-8955, de Leon, Jose; https://orcid.org/0000-0002-7756-2314, De las Cuevas, Carlos; https://orcid.org/0000-0001-5742-905X, Sanz, Emilio J; https://orcid.org/0000-0001-6788-4435, Gross, Jason A; https://orcid.org/0009-0000-9696-8267, Correll, Christoph U; https://orcid.org/0000-0002-7254-5646, Verdoux, Hélène; https://orcid.org/0000-0003-2948-3782, Lally, John; https://orcid.org/0000-0003-3038-0625, de Filippis, Renato; https://orcid.org/0000-0001-6928-1224, Schulte, Peter F J; https://orcid.org/0000-0003-4931-3393, Molden, Espen; https://orcid.org/0000-0001-6190-2751, Arrojo-Romero, Manuel; https://orcid.org/0000-0002-5609-7134, Bostrom, Adrian D; https://orcid.org/0000-0001-8604-9638, Schoretsanitis, Georgios; https://orcid.org/0000-0002-3851-4117, Fernandez-Egea, Emilio; https://orcid.org/0000-0003-4128-8955, and de Leon, Jose; https://orcid.org/0000-0002-7756-2314

Abstract

Background: Pharmacovigilance studies indicate clozapine history is marked by adverse drug reactions (ADRs). Objective: In a 2021 article, the United Kingdom (UK) had >90 % of European clozapine-related fatal outcomes in VigiBase, the World Health Organization's pharmacovigilance database. Two possibly opposing hypotheses could explain this disparity: 1) fewer reported fatal outcomes in other Western European countries mainly reflect underreporting to VigiBase, and 2) the higher number of UK reports reflects higher real relative mortality. Methods: VigiBase reports from clozapine's introduction to December 31, 2022, were studied for ADRs and the top 10 causes of fatal outcomes. The UK was compared with 11 other top reporting Western countries (Germany, Denmark, France, Finland, Ireland, Italy, Netherlands, Norway, Spain, Sweden and Switzerland). Nine countries (except Ireland and Switzerland) were compared after controlling for population and clozapine prescriptions. Results: The UK accounted for 29 % of worldwide clozapine-related fatal outcomes, Germany 2 % and <1 % in each of the other countries. The nonspecific label "death" was the top cause in the world (46 %) and in the UK (33 %). "Pneumonia" was second in the world (8 %), the UK (12 %), Ireland (8 %) and Finland (14 %). Assuming that our corrections for population and clozapine use are correct, other countries underreported only 1-10 % of the UK clozapine fatal outcome number. Conclusions: Different Western European countries consistently underreport to VigiBase compared to the UK, but have different reporting/publishing styles for clozapine-related ADRs/fatal outcomes. Three Scandinavian registries suggest lives are saved as clozapine use increases, but this cannot be studied in pharmacovigilance databases.

Published
2024

26. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

Author

De las Cuevas, Carlos, primary, Sanz, Emilio J., additional, Gross, Jason A., additional, Correll, Christoph U., additional, Verdoux, Hélène, additional, Lally, John, additional, de Filippis, Renato, additional, Schulte, Peter F.J., additional, Molden, Espen, additional, Arrojo-Romero, Manuel, additional, Bostrom, Adrian D., additional, Schoretsanitis, Georgios, additional, Fernandez-Egea, Emilio, additional, and de Leon, Jose, additional

Published
2023
Full Text
View/download PDF

31. Shared Risks and Interests : The Case for Private Sector Engagement in Water Policy and Management

Author

Schulte, Peter, Orr, Stuart, Morrison, Jason, Gleick, Peter H., editor, Ajami, Newsha, Series editor, Christian-Smith, Juliet, Series editor, Cooley, Heather, Series editor, Donnelly, Kristina, Series editor, Fulton, Julian, Series editor, Ha, Mai-Lan, Series editor, Heberger, Matthew, Series editor, Moore, Eli, Series editor, Morrison, Jason, Series editor, Orr, Stewart, Series editor, Schulte, Peter, Series editor, and Srinivasan, Veena, Series editor

Published
2014
Full Text
View/download PDF

38. Analytische Sprachphilosophie

Author

Felka, Katharina, Schnieder, Benjamin, Zimmermann, Thomas Ede, Hoeltje, Miguel, Schroeder, Severin, Kemmerling, Andreas, Harth, Manfred, Keil, Geert, Dänzer, Lars, Prien, Bernd, Lötscher, Nathalie, Conrad, Sarah-Jane, Schulte, Peter, Nimtz, Christian, and Kompa, Nikola, editor

Published
2015
Full Text
View/download PDF

41. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition

Author

Schoretsanitis, Georgios, primary, Anıl Yağcıoğlu, A. Elif, additional, Ruan, Can-Jun, additional, Eap, Chin B., additional, Molden, Espen, additional, Baptista, Trino, additional, Clark, Scott R., additional, Fernandez-Egea, Emilio, additional, Kim, Se Hyun, additional, Lane, Hsien-Yuan, additional, Leung, Jonathan, additional, Maroñas Amigo, Olalla, additional, Motuca, Mariano, additional, Olmos, Ismael, additional, Every-Palmer, Susanna, additional, Procyshyn, Ric M., additional, Rohde, Christopher, additional, Satish, Suhas, additional, Schulte, Peter F.J., additional, Spina, Edoardo, additional, Takeuchi, Hiroyoshi, additional, Verdoux, Hélène, additional, Correll, Christoph U., additional, and de Leon, Jose, additional

Published
2023
Full Text
View/download PDF

42. Escaping the Long Shadow Cast by Agranulocytosis

Author

de Leon, Jose, primary, Arrojo-Romero, Manuel, additional, Verdoux, Hélène, additional, Ruan, Can-Jun, additional, Schoretsanitis, Georgios, additional, Rohde, Christopher, additional, Cohen, Dan, additional, Schulte, Peter F.J., additional, Kim, Se Hyun, additional, Cotes, Robert O., additional, Leung, Jonathan G., additional, Otsuka, Yuji, additional, Kirilochev, Oleg O., additional, Baptista, Trino, additional, Grover, Sandeep, additional, Every-Palmer, Susanna, additional, Clark, Scott R., additional, McGrane, Ian R., additional, Motuca, Mariano, additional, Olmos, Ismael, additional, Wilkowska, Alina, additional, Sagud, Marina, additional, Anıl Yağcıoğlu, A. Elif, additional, Ristic, Dragana Ignjatovic, additional, Lazary, Judit, additional, Sanz, Emilio J., additional, and De Las Cuevas, Carlos, additional

Published
2023
Full Text
View/download PDF

43. GN&C Sequencing for Orion Rendezvous, Proximity Operations, and Docking

Author

Schulte, Peter Z, Spehar, Peter T, and Woffinden, David C

Subjects
Astrodynamics
Abstract

As part of the Artemis program to return humans to the lunar surface, the National Aeronautics and Space Administration is planning to use the Orion Multi- Purpose Crew Vehicle to transport crew to a small orbital platform called Gate- way in cislunar space. To facilitate this activity, Orion is required to perform Rendezvous, Proximity Operations, and Docking (RPOD) with both the Gate- way and the launch vehicle upper stage. The Orion spacecraft uses sequencing in the form of Phases, Segments, Activities, and Modes (PSAM) to configure Guidance, Navigation, & Control (GN&C) software during each portion of the mission. Significant updates to Orion PSAM definitions are required for RPOD. This paper describes the process of defining these new sequencing elements, implementing them in prototype flight software, and testing them in an integrated simulation environment. First, requirements are specified to determine the nominal and off-nominal sequencing behavior necessary to complete the mission. These requirements also specify which software functions should be fully autonomous and which functions require manual interactions from crew or ground operators. Next, the RPOD concept of operations is defined with detailed events listed in a mission timeline. Third, a state machine diagram is developed to show all PSAM states, including all possible transitions between them. After this, the PSAM states and transitions are entered into a sequencing software emulator and parameter values and modes are defined for GN&C software elements. Finally, the PSAM architecture is tested within an integrated simulation environment by connecting it with prototypes of relevant GN&C flight software elements and with detailed vehicle models. After the sequencing design has been finalized and tested, it is implemented in flight software.

Published
2020

44. Escaping the Long Shadow Cast by Agranulocytosis:Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom

Author

de Leon, Jose, Arrojo-Romero, Manuel, Verdoux, Hélène, Ruan, Can-Jun, Schoretsanitis, Georgios, Rohde, Christopher, Cohen, Dan, Schulte, Peter F.J., Kim, Se Hyun, Cotes, Robert O., Leung, Jonathan G., Otsuka, Yuji, Kirilochev, Oleg O., Baptista, Trino, Grover, Sandeep, Every-Palmer, Susanna, Clark, Scott R., McGrane, Ian R., Motuca, Mariano, Olmos, Ismael, Wilkowska, Alina, Sagud, Marina, Anil Yağcioğlu, A. Elif, Ristic, Dragana Ignjatovic, Lazary, Judit, Sanz, Emilio J., and De Las Cuevas, Carlos

Subjects
clozapine/adverse effects, clozapine/administration and dosage, clozapine/metabolism, clozapine/therapeutic use, clozapine/toxicity, COVID-19, drug labeling, infection, inflammation, mortality/drug effects, pneumonia, schizophrenia, sex, smoking, drug labeling, mortality/drug effects, clozapine/therapeutic use, COVID-19, clozapine/toxicity, infection, smoking, clozapine/administration and dosage, schizophrenia, Psychiatry and Mental health, clozapine/metabolism, inflammation, clozapine/adverse effects, pneumonia, sex, Pharmacology (medical)
Abstract

Purpose/Background A recent article in this journal presented a US perspective regarding the modernization of clozapine prescription and proposed an escape from the long shadow cast by agranulocytosis. Methods Here, an international group of collaborators discusses a point of view complementary to the US view by focusing on worldwide outcomes of clozapine usage that may be uneven in terms of frequency of clozapine adverse drug reactions. Findings/Results Studies from the Scandinavian national registries (Finland and Denmark) did not find increased mortality in clozapine patients or any clear evidence of the alleged toxicity of clozapine. Data on clozapine-associated fatal outcomes were obtained from 2 recently published pharmacovigilance studies and from the UK pharmacovigilance database. A pharmacovigilance study focused on physician reports to assess worldwide lethality of drugs from 2010 to 2019 found 968 clozapine-associated fatal outcomes in the United Kingdom. Moreover, the United Kingdom accounted for 55% (968 of 1761) of worldwide and 90% (968 of 1073) of European fatal clozapine-associated outcomes. In a pharmacovigilance study from the UK database (from 2008 to 2017), clozapine was associated with 383 fatal outcomes/year including all reports from physicians and nonphysicians. From 2018 to 2021, UK clozapine-associated fatal outcomes increased to 440/year. Implications/Conclusions The interpretation of fatal outcomes in each country using pharmacovigilance databases is limited and only allows gross comparisons; even with those limitations, the UK data seem concerning. Pneumonia and myocarditis may be more important than agranulocytosis in explaining the uneven distribution of fatal outcomes in clozapine patients across countries.

Published
2023
Full Text
View/download PDF

46. The Caché Object Model

Author

Kirsten, Wolfgang, Ihringer, Michael, Schulte, Peter, Röhrig, Bernhard, Kirsten, Wolfgang, Ihringer, Michael, Schulte, Peter, and Röhrig, Bernhard

Published
2001
Full Text
View/download PDF

48. Object Access and Persistency

Author

Kirsten, Wolfgang, Ihringer, Michael, Schulte, Peter, Röhrig, Bernhard, Kirsten, Wolfgang, Ihringer, Michael, Schulte, Peter, and Röhrig, Bernhard

Published
2001
Full Text
View/download PDF

50. SQL Access and Tables

Author

Kirsten, Wolfgang, Ihringer, Michael, Schulte, Peter, Röhrig, Bernhard, Kirsten, Wolfgang, Ihringer, Michael, Schulte, Peter, and Röhrig, Bernhard

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results